Paige.AI Receives FDA’s Breakthrough Designation for its Artificial Intelligence in Pathology
Shots:
- FDA grants BT designation to Paige.AI to develop AI in computational pathology for the diagnosis and treatment of cancer including prostate cancer
- The FDA’s BT designation is granted for technologies that provide effective diagnosis and treatment for life-threatening diseases
- Paige.AI is based on Fuch’s technology, works with the de-identified dataset to develop AI portfolio targeting multiple cancer across the world
Click here to read full press release/ article | Ref: Business Wire | Image: Medium